Royalty Pharma Q1 Profit and Revenue Rise; Raises 2026 Portfolio Receipts Outlook

Royalty Pharma plc (Nasdaq: RPRX) reported first‑quarter 2026 results on May 6, 2026, showing double‑digit growth in its key cash metrics and a raised full‑year outlook for Portfolio Receipts. Management highlighted robust royalty performance and active transaction activity as drivers of the strong start to 2026.

The company reported Royalty Receipts of $887 million, up 13% year‑over‑year, and Portfolio Receipts of $925 million, up 10% versus Q1 2025. Capital deployment totaled $528 million in the quarter and Royalty Pharma announced new transactions with an aggregate committed value of up to $1.25 billion. During the quarter the company repurchased roughly 1.1 million Class A shares for $50 million and increased its quarterly dividend to $0.235 per share.

Operational cash generation was strong: net cash provided by operating activities was $718 million, adjusted EBITDA was $889 million and Portfolio Cash Flow was $722 million for the quarter. As of March 31, 2026, Royalty Pharma reported $586 million of cash and cash equivalents and total principal debt of $9.2 billion, reflecting a capital‑intensive model that balances acquisitions, dividends and buybacks.

The company highlighted strategic R&D co‑funding agreements with Johnson & Johnson and Teva as examples of its evolving business model, alongside several positive clinical and regulatory developments across the royalty portfolio that supported growth. Management also noted that the completion of the internalization transaction reduced management fee expense and is expected to lower operating cost ratios going forward.

Royalty Pharma raised its 2026 Portfolio Receipts guidance to a range of $3.325 billion to $3.45 billion, excluding contributions from transactions announced after the release date, and expects Royalty Receipts growth of approximately 4%–8% for the year; the guidance assumes current FX rates yield a modest ~+1% tailwind. Market observers say the company’s combination of predictable cash receipts, active deployment capacity and shareholder returns positions it to continue growing its portfolio and returning capital, though outcomes will depend on future transaction cadence and product performance.